Cancer Gene Therapy
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 6.4 | Q1 | 89.6% | 1.749 | Q1 | 93.9% |
| 2024 | 5.0 | Q1 | 86.4% | 1.727 | Q1 | 94.0% |
| 2023 | 4.8 | Q1 | 76.2% | 1.457 | Q1 | 92.3% |
| 2022 | 6.4 | Q1 | 81.1% | 1.384 | Q1 | 92.0% |
| 2021 | 5.9 | Q2 | 73.1% | 1.207 | Q2 | 90.0% |
| 2020 | — | — | 1.535 | Q1 | 92.7% | |
| 2019 | — | — | 0.930 | Q2 | 84.1% | |
| 2018 | — | — | 1.233 | Q2 | 88.4% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
0929-1903
ISSN
1476-5500
country
UScoverage
1994-2026